Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 392 participants.
Also called NCT05238012
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 392 participants
- Sponsor
- Registry
-
NCT05238012
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05238012. Randomized; no masking; primary purpose treatment. Start 2022-08-02 (actual); primary completion 2024-04-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes
- Acronym
- XTREME
- Condition
- Metabolism Disorder, Lipid
- Condition
- Metabolism Disorder, Glucose
- Intervention (Drug)
- Xuezhikang Capsule
- Intervention (Drug)
- Atorvastatin Calcium Tablets
- Lead sponsor
- Heart Health Research Center
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct05238012- Content hash
e50d633c0118908e4c343caa1753fa0e2cfebec581b93bebf5345be036874e3a